Suppr超能文献

[软骨保护疗法对下腰痛患者的抗吸收细胞因子作用]

[Antiresorptive-cytokine effects of the chondroprotective therapy in patients with lower back pain].

作者信息

Zolotovskaya I A, Davydkin I L

机构信息

Samara State Medical University, Samara, Russia.

出版信息

Zh Nevrol Psikhiatr Im S S Korsakova. 2020;120(4):65-71. doi: 10.17116/jnevro202012004165.

Abstract

OBJECTIVE

To evaluate the antiresorptive-cytokine effects of chondroitin sulfate on non-specific lower back pain in patients with knee osteoarthritis (OA).

MATERIALS AND METHODS

Using the envelope method, 231 patients were randomized into two groups: group 1 (=116, main) received nonsteroidal anti-inflammatory drugs (NSAIDs) and chondrogard, group 2 (=115, comparison) received only NSAIDs. The 2-month study included 3 visits (V): V - at the beginning of the study, V - after 10 days, V - after 60 days with the assessment of blood parameters: transforming growth factor β1 (TFR β1), interleukin (IL)-1β and IL-6, beta-Crosslaps, bone matrix formation indicator P1NP (n-terminal propeptide procollagen type 1), and determination of the level of deoxypyridinoline (DPID) in the urine.

RESULTS AND CONCLUSION

At the end of the study, there is a significant decrease in all studied cytokines in patients of group 1 compared to group 2, as well as indicators of beta-Crosslaps (<0,001) and DPID (<0,001), which may indicate the presence of its own antiresorptive-cytokine effect in chondroitin sulfate.

摘要

目的

评估硫酸软骨素对膝骨关节炎(OA)患者非特异性下背痛的抗吸收细胞因子作用。

材料与方法

采用信封法,将231例患者随机分为两组:第1组(n = 116,主要组)接受非甾体抗炎药(NSAIDs)和chondrogard,第2组(n = 115,对照组)仅接受NSAIDs。为期2个月的研究包括3次访视(V):V1 - 在研究开始时,V2 - 10天后,V3 - 60天后,评估血液参数:转化生长因子β1(TGFβ1)、白细胞介素(IL)-1β和IL-6、β-交联C端肽、骨基质形成指标P1NP(I型前胶原N端前肽),并测定尿中脱氧吡啶啉(DPID)水平。

结果与结论

研究结束时,与第2组相比,第1组患者所有研究的细胞因子以及β-交联C端肽(<0.001)和DPID(<0.001)指标均显著降低,这可能表明硫酸软骨素具有自身的抗吸收细胞因子作用。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验